Alvotech Q4 FY2025 earnings call

Robert Westman highlighted 2025 was important for the company, strengthening position as a leading global biosimilar developer, expanding commercial footprint, advancing pipeline, and strengthening financial position. Lisa Graver discussed commercial update, including expansion of commercial footprint, reliable supply, and positioning for US market. Joseph McClellan talked about status of US regulatory submissions, progress in development pipeline, and recent FDA draft guidance. Linda Young-Stathier concluded with financial results, noting Q4 2025 revenues up 13%, full year 2025 revenues up 21%, adjusted EBITDA up 27%, and strong cash balance supported by financing transactions.

In 2025, total revenues increased by 20% to $591 million, while adjusted EBITDA increased by 27% to $137 million. Product revenues were driven by commercial momentum for AVTO2 and AVTO4. Licensing revenues were a key driver in Q4 2025, making up 75% of total revenues. Gross margin was 66% in Q4 2025 and 61% for the full year 2025.

Reaffirms 2026 revenue outlook in the range of $650 to $700 million, reflecting continued double-digit sales growth. Lower end of range assumes no US launches in 2026. Adeptity data expected to increase to $180 to $220 million. Working towards cash flow positivity by year end 2026.

No specific risks explicitly detailed in the provided transcript other than general risks and uncertainties outlined in company filings with the SEC that could cause actual results to differ from forward-looking statements.

Q: On U.S. approvals, sense of pending items and confidence in approval, chances of additional FDA inspection; and on 2026 guidance, impact of US launches.

A: Joseph McClellan said remediation efforts completed, compiling info to submit by first half of 2026, and there's opportunity for FDA inspection again but working to have comprehensive response. Linda said lower end of 2026 guidance range assumes no US launches.

Q: On 2026 guidance, incremental commercial approvals outside US; and on manufacturing platform expansion, timing, cost, and impact of FDA draft guidance on R&D costs.

A: Linda said guidance includes momentum from launches already approved in Europe and rest of world, and targeting US approvals. Lisa said dual sourcing and capacity building is a first half event, within scope of expectations in terms of spend.

Q: On aims and ambitions as new CEO, short-term priorities; and on Iran war disruption risk and competitive landscape mitigation.

A: Lisa said it's evolution, not revolution, priority is executing pipeline and launching programs through partners. On Iran war, no immediate direct impact on procurement or supply. On competitive landscape, anticipated regulatory changes, speed of development, IP positioning, and first mover advantage.

Q: On established portfolio momentum, revenue growth trajectory of O2 and O4; and on R&D spend sequencing.

A: Joseph said growth in O2 and O4 expected in 2026, with continued momentum in US through partnership with Teva. Amanda said R&D spend will be fairly balanced in 2026, expecting back and loaded towards end of Q4.

Q: On Humira biosimilar market dynamics, private label sales in US, and guidance high end and product gross margin.

A: Joseph said continued growth in Humira biosimilar market, formulary business focus. Robert said high end of 2026 guidance reflects growth in supply revenues. Robert said product gross margin negative due to facility improvements, expecting to trend up in 2026